Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas - Wikidata - wikimedia - TriplyDB

Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas

Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas

http://www.wikidata.org/entity/Q35195304

about

Trial watch - inhibiting PARP enzymes for anticancer therapy Role of Biomarkers in the Development of PARP Inhibitors PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer Inhibition of Topoisomerase (DNA) I (TOP1): DNA Damage Repair and Anticancer Therapy PARP inhibitors in the management of breast cancer: current data and future prospects Profile of veliparib and its potential in the treatment of solid tumors PARPs and the DNA damage response The Valley of Death in anticancer drug development: a reassessment Chemotherapeutic compounds targeting the DNA double-strand break repair pathways: the good, the bad, and the promising Advances in using PARP inhibitors to treat cancer Use of the γ-H2AX assay to monitor DNA damage and repair in translational cancer research PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours.A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511).A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187.The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis.Dynamic regulation of Rad51 by E2F1 and p53 in prostate cancer cells upon drug-induced DNA damage under hypoxia Synthesis, [¹⁸F] radiolabeling, and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography.PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.Enhancing synthetic lethality of PARP-inhibitor and cisplatin in BRCA-proficient tumour cells with hyperthermia.The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice Poly(ADP-ribose) polymerase inhibitors sensitize cancer cells to death receptor-mediated apoptosis by enhancing death receptor expression.Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors.Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition Molecular pathways: targeting ETS gene fusions in cancer.Mutations of human DNA topoisomerase I at poly(ADP-ribose) binding sites: modulation of camptothecin activity by ADP-ribose polymers.Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.Treating breast cancer in the 21st century: emerging biological therapies Development of synthetic lethality anticancer therapeutics.Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor tissues An update on PARP inhibitors for the treatment of cancer The histone methyltransferase SMYD2 methylates PARP1 and promotes poly(ADP-ribosyl)ation activity in cancer cells.Characterization of Batracylin-induced Renal and Bladder Toxicity in Rats

P2860

Q26745673-ECF1C012-9396-45BA-84DB-5C9386B5A8B7 Q26753159-2541F866-8728-4BCA-B54F-BD177A19BA7B Q26768661-1FEC217B-F9EB-4A86-B8C4-63054B7D6204 Q26783551-4B259680-2CB4-4BB7-ABC3-3E63ACCEE6B7 Q26796576-7F481740-028C-4467-85C9-C3F509B60746 Q26798352-1DC072FD-CA66-4F11-917B-C7A6C64C39D4 Q26801272-D179B110-2AEF-4658-A631-AF73F6F18261 Q26859010-299E3568-B425-4A2F-88CB-C9AD1573E52C Q26861274-BEC2928B-211F-47F6-ADA2-51603A32071A Q26863501-7E601CEB-A660-4D55-85D4-03739A93B31D Q27003972-02DBEE10-5B50-44EB-8130-DA8CE019EE2F Q27023686-69855D1A-0119-413C-BB50-140A4AF6634D Q27027503-BBEE30BE-E7BF-4A50-A72D-A0E5ED63A650 Q27302763-37D01F3F-8EE0-4091-B12A-EC5FCE217E0A Q27304386-02998A2D-5B39-49F8-B16A-EEEAC67DFC69 Q27318449-BC3C222E-3CCD-478F-B57C-C4D3D37842C2 Q28072204-1F4E3E16-C3F4-4295-963C-A35D69859195 Q33410375-806BEDEC-654B-4130-BF67-3AA68E1D315D Q33415790-4A6871DF-0D7E-4249-ACC7-4FBB5095FFCE Q33416440-F755EA58-96C8-49B6-98EA-6508A3522CEB Q33422932-5A132CFC-1F0B-45C3-857F-BBE5289581FF Q33431474-D9DC3039-9F8C-4B5B-8140-A0847DDFB329 Q33553318-4D251E6D-E59A-4F4D-B93C-20BCFF3F4796 Q33584594-682FFFF3-0D36-429D-B37B-08CB60E7043B Q33607384-E9DD0B2B-E9BA-43F7-B625-C60F77C47709 Q33617922-5AAA1AD8-CAFB-4F72-B89C-1314D59E7DCA Q33709593-7FAC63F9-465B-4590-AAB8-384EC6F7AAAD Q33874466-2E0ADC05-F86E-457C-8411-0734820AEAF5 Q33947014-5F3E05D1-335D-4B3C-BDE0-90E8138B5881 Q33954553-31E9A6A7-E58E-48E2-8DD4-C0019BC93CAA Q34034221-F09532A6-621C-4238-AC91-EF3FEF552790 Q34135434-B5C5DE4C-E294-4B64-A7ED-BD106B4E1457 Q34234110-FD1A444B-5DE4-45A0-BB0F-CC25D6C66914 Q34309488-37DCED70-0FDD-497C-9835-97241DEF4540 Q34326536-D2FFDCAA-343B-4FC3-80C1-7EA75570B305 Q34380368-C60F826F-7577-4719-BD7E-D349A087867D Q34531543-36B0AA9E-E9CA-4F8C-9006-19F091F0C34F Q35142718-413151AC-B025-45E7-B423-A013986919DF Q35146271-A4B74C28-07FE-46C8-9A4D-61B58FEDFD00 Q35243854-19A6F3B0-89A3-4FD8-B605-EE04F1F9D8FA

P2860

Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas

http://www.wikidata.org/entity/Q35195304

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Phase I study of PARP inhibito ...... ory solid tumors and lymphomas

@ast

Phase I study of PARP inhibito ...... ory solid tumors and lymphomas

@en

type

label

Phase I study of PARP inhibito ...... ory solid tumors and lymphomas

@ast

Phase I study of PARP inhibito ...... ory solid tumors and lymphomas

@en

prefLabel

Phase I study of PARP inhibito ...... ory solid tumors and lymphomas

@ast

Phase I study of PARP inhibito ...... ory solid tumors and lymphomas

@en

P1433

Q35195304-203CD977-6D8F-42B7-9974-F36B1EB82E2C

P1476

Q35195304-9C4F6BD3-8B55-4DC6-B37B-2377213A41FE

P2093

Q35195304-0DC505E4-0A66-4314-92BC-A161684340C8

Q35195304-1AEBC960-91C8-4033-A1EE-EEA99D88DED2

Q35195304-1EC3FEA0-8DBB-4137-A21F-BFC7931094EC

Q35195304-21CBBAD1-7F2A-491D-ABF3-53B9B3E6CF63

Q35195304-5879454A-11C6-4312-A397-CDDA98BCF828

Q35195304-5CD19EDA-55D8-40D5-AC21-3048085A4104

Q35195304-75E8ED00-A12A-41EC-82A6-6D6DBEA2058E

Q35195304-7A582C15-F268-4C31-A63E-EFC5E0ADDA0A

Q35195304-7B96EAC9-2E5E-41AC-AD9B-B2914C48F485

Q35195304-80CF3523-C1C3-4A81-AE94-2CA28B4D5A67

P2860

Q35195304-0C84798F-D30D-4B8B-9D7B-AC5C835024D5

Q35195304-158F0339-6747-45AB-B7EE-9FDAC7BE6EFD

Q35195304-1B6D3B30-B367-40E7-91A3-07BCDE29CD5E

Q35195304-1C7AD8BE-51A1-4BB1-B168-2D890B091042

Q35195304-20F40AD6-6555-4F57-B7A4-4E8078E24262

Q35195304-24D1639C-3599-4C5A-AFC7-CF0C372BDDA7

Q35195304-28B17A2D-85D2-41C6-AF23-F47B65EB4387

Q35195304-3C74AA01-8370-461F-87E4-784E792D3C5E

Q35195304-3CF8C967-1268-4795-8145-4677BF0D91D6

Q35195304-4EE6AD28-C95A-4273-B5BD-973AA7B283F9

P304

Q35195304-D8E7CC1C-6486-48C0-B726-1CBA6AB431A3

P31

Q35195304-30BAC8A6-8EE2-400E-9C96-53950B681194

P356

Q35195304-E8437D5C-FB6D-48DA-9E8F-4453689024EE

P407

Q35195304-DB3BCF16-6B8D-4DCA-8D32-1221F0A05918

P433

Q35195304-908BE147-86AC-4CF8-9376-B7FFEC9E4247

P478

Q35195304-F5ACB3A0-9806-4394-B655-B958D35E24E3

P50

Q35195304-8EA9D86C-C337-4F82-B25C-719E58FA36C8

P577

Q35195304-E5218E91-1707-4F82-A29C-7ECB78FE2192

P698

Q35195304-554EBCFE-5867-4C30-BE3A-FD3910029145

P921

Q35195304-D44F3939-95E8-47CC-BDED-284959E2B66C

P932

Q35195304-DBB6EBCC-E131-457E-B7FC-C89D6068378E

P356

0008-5472.CAN-11-1227

P1433

Cancer Research

P1476

Phase I study of PARP inhibito ...... ory solid tumors and lymphomas

@en

P2093

Alice Chen

http://www.w3.org/2001/XMLSchema#string

Anthony J Murgo

http://www.w3.org/2001/XMLSchema#string

Giovanna Speranza

http://www.w3.org/2001/XMLSchema#string

Giovanni Melillo

http://www.w3.org/2001/XMLSchema#string

Howard Stotler

http://www.w3.org/2001/XMLSchema#string

James H Doroshow

http://www.w3.org/2001/XMLSchema#string

Jiuping Ji

http://www.w3.org/2001/XMLSchema#string

Joel M Reid

http://www.w3.org/2001/XMLSchema#string

John Carter

http://www.w3.org/2001/XMLSchema#string

Joseph E Tomaszewski

http://www.w3.org/2001/XMLSchema#string

P2860

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

GammaH2AX and cancer

Topoisomerase I inhibitors: camptothecins and beyond

A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies.

Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cells

Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity.

The PARP superfamily.

Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells.

P304

5626-5634

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-11-1227

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-07-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21795476

http://www.w3.org/2001/XMLSchema#string

P921

P932

3166628

http://www.w3.org/2001/XMLSchema#string